Zach Coffell

Zach’s investment career began on his 20th birthday when his father gave him a copy of The Intelligent Investor, by Benjamin Graham, and the website address! He believes in buying quality companies with durable competitive advantages and his ideal holding period is forever. Zach owns shares in: (LSE: BOO), Craneware (LSE: CRW), GlaxoSmithKline (LSE: GSK), ITE Group (LSE: ITE), Judges Scienfitic (LSE: JDG), Royal Dutch Shell (LSE: RDSB), Somero (LSE: SOM), Tasty (LSE: TAST)

Why I’d ditch IQE plc for Royal Dutch Shell plc

There's a speculative aspect to both IQE plc (LSE: IQE) and oil behemoth Royal Dutch Shell plc (LON: RDSB), but the latter seems the... More »

Should you buy this growth company after profits soar 40%?

The market reacted negatively to this company's explosive profit growth today. One Fool takes a closer look. More »

Smash profit warning paralysis with this three-step guide

Unexpected bad news can leave us all feeling lost. Take back control after a profit warning with these simple steps. More »

Could these value stocks double by 2019?

The market hates these quality businesses, says one Fool. But could the shares skyrocket and even double in a few years? More »

Here’s how this stock turned £1,000 into £19,000

These two companies have smashed the market by huge margins. Can they continue to do so? More »

Why I’d buy AstraZeneca plc for fat dividends and pipeline potential

The expiry of blockbuster patents has led some to doubt AstraZeneca plc (LON: AZN), but one Fool believes the company can innovate its way... More »

Are these the worst ‘growth’ stocks on the market?

There's barnstorming revenue rises on show at these growth champions, but shareholder returns could head in the opposite direction says One Fool. More »

These under-the-radar income stocks offer market-beating payouts

These little-known stocks offer massive dividend payouts, but are they really better buys than FTSE100 dividend giants? More »

Why I’d swap this overpriced share for this bargain growth stock

One Fool would sidestep one popular share for an under-the-radar small-cap. More »

Why I’d sell Fevertree Drinks plc’s explosive growth for A.G. Barr plc’s dividend

One Fool believes excessive market expectations stack the odds against Fevertree Drinks plc (LON: FEVR), but low expectations for A.G. Barr plc (LON: BAG)... More »

Why I’d dump Purplebricks Group plc and this fellow growth champion

One Fool doesn't buy into the hype surrounding these rapidly expanding companies. More »

1 value stock I’d buy and 1 I’d sell

A low P/E rating doesn't necessarily mean a bargain. One Fool explains why he's sceptical of flattering headline figures and introduces a stock with... More »

Why profits should explode at these capital-light businesses

Low re-investment requirements at these companies could see profits snowball, says one Fool. More »

2 Buffett-style income stocks for retirees

You should consider tucking away these income stocks, say one Fool. More »

2 stocks at 52-week highs that could still be worth buying

Don't let 'high' stock prices put you off these wonderful growth companies, warns one Fool. More »

Three AIM survival rules that could make you a millionaire

Afraid of AIM (INDEXFTSE:AXX) disasters? Apply these guidelines and you'll do just fine, says one Fool. More »

Hikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain

Could ongoing approval issues at Hikma Pharmaceuticals plc (LON: HIK) and rivals help GlaxoSmithKline plc (LON:GSK) preserve its dividend? More »

Is BP plc’s 6% yield safe in the “new oil price environment”?

Can Royal Dutch Shell plc (LON:RDSB) and BP plc (LON:BP) maintain cumbersome payouts in a "lower for longer" environment? More »

These two “competitive advantages” could be about to crumble

These much-loved businesses could be picked apart by competition, says one Fool. More »

Despite a P/E of 5, this stock is no bargain

This low price-to-earnings stock could be a value trap. More »